Pancreatic cancer: Advances in treatment
Pancreatic cancer: Advances in treatment作者机构：The Elkins Pancreas CenterMichael E DeBakey Department of Surgeryand Dan L Duncan Cancer CenterBaylor College of Medicine
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2014年第20卷第28期
页 面：9354-9360页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Pancreatic cancer Pancreaticoduodenectomy Treatment advances Pancreatic oncology Chemotherapy FOLFIRINOX Pancreatic resection
摘 要：Pancreatic cancer is a leading cause of cancer mortality and the incidence of this disease is expected to continue *** patients with pancreatic cancer have traditionally faced a dismal prognosis,over the past several years various advances in diagnosis and treatment have begun to positively impact this *** of effective combinations of existing chemotherapeutic agents,such as the FOLFIRINOX and the gemcitabine+nab-paclitaxel regimen,has improved survival for selected patients although concerns regarding their toxicity profiles remain.A better understanding of pancreatic carcinogenesis has identified several pre-malignant precursor lesions,such as pancreatic intraepithelial neoplasias,intraductal papillary mucinous neoplasms,and cystic *** technology has also evolved dramatically so as to allow early detection of these lesions and thereby facilitate earlier *** remains a cornerstone of treatment for patients with resectable pancreatic tumors,and advances in surgical technique have allowed patients to undergo resection with decreasing perioperative morbidity and *** has also become feasible in selected patients with borderline resectable tumors as a result of neoadjuvant ***,pancreatectomy involving vascular reconstruction and pancreatectomy with minimally invasive techniques have demonstrated safety without significantly compromising oncologic ***,a deeper understanding of molecular aberrations contributing to the development of pancreatic cancer shows promise for future development of more targeted and safe therapeutic agents.
维普期刊数据库